{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.90","value":"84.19"}]}],"title":"Dacomitinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.58","value":"12.77"}]}],"title":"PF-05199265"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Cmax was defined as maximum observed plasma concentration and can be observed directly from data.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG000","title":"Dacomitinib"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) analysis set included all participants who were treated with dacomitinib with at least 1 measured plasma concentration and were dose-compliant (who received 45 mg dacomitinib daily without interruptions/dose reductions for at least 14 days prior to day of data collection). This outcome measure was planned to be analyzed in Chinese subgroup only.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)","title":"Maximum Observed Plasma Concentration (Cmax) of Dacomitinib and Its Metabolite PF-05199265","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}